FDA Rejects AMT-130 Phase I/II Data for Marketing Application, Recommends Phase III Study

summarizeSummary

The FDA has rejected uniQure's Phase I/II data for AMT-130 as insufficient for a marketing application, requiring a full Phase III trial, significantly delaying its lead program. The company also reported an extended cash runway but faced setbacks in other pipeline candidates.

check_boxKey Events

• FDA Rejects AMT-130 Phase I/II Data for Marketing Application

  The U.S. Food and Drug Administration (FDA) informed uniQure that its Phase I/II study data for AMT-130, an investigational gene therapy for Huntington's disease, is not sufficient to support a marketing application.

• FDA Recommends Full Phase III Study

  The FDA strongly recommended uniQure conduct a prospective, randomized, double-blind, sham surgery-controlled Phase III study, significantly extending the development timeline and costs for the lead candidate.

• Extended Cash Runway into Second Half of 2029

  The company reported cash, cash equivalents, and current investment securities of $622.5 million as of December 31, 2025, which is expected to fund operations into the second half of 2029, largely due to prior public offerings.

• Setbacks in Other Pipeline Programs

  Dosing in mid- and high-dose cohorts for AMT-191 (Fabry disease) has been paused due to dose-limiting toxicities, and enrollment for AMT-162 (ALS) remains on voluntary pause following a serious adverse event.

auto_awesomeAnalysis

uniQure N.V. announced a significant regulatory setback for its lead gene therapy candidate, AMT-130 for Huntington's disease. The FDA has stated that the Phase I/II study data, even with positive 36-month results, is insufficient to support a marketing application and strongly recommended a prospective, randomized, double-blind, sham surgery-controlled Phase III study. This decision significantly delays the potential market entry for AMT-130 and will require substantial additional investment in a lengthy clinical trial. While the company reported a strong cash position of $622.5 million, extending its runway into the second half of 2029, this capital will now be needed to fund the newly required Phase III trial. Additionally, other pipeline programs, AMT-191 and AMT-162, reported safety concerns leading to paused dosing or enrollment, adding to the overall negative sentiment regarding the company's clinical progress.